Asparaginase Escherichia coli
- Generic Name
- Asparaginase Escherichia coli
- Brand Names
- Rylaze, Spectrila
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9015-68-3
- Unique Ingredient Identifier
- G4FQ3CKY5R
- Background
Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exh...
- Indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 470
- Registration Number
- NCT00967057
- Locations
- 🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
🇦🇺Women's and Children's Hospital, North Adelaide, South Australia, Australia
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- B-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Lymphoblastic Lymphoma
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateDrug: cytarabineDrug: prednisoneDrug: bortezomibDrug: pegaspargaseDrug: methotrexateDrug: etoposide phosphateDrug: cyclophosphamideBiological: filgrastimDrug: leucovorin calciumOther: laboratory biomarker analysisDrug: High Dose MTX
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00873093
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT00854425
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia
- Conditions
- Interventions
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 199
- Registration Number
- NCT00784017
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: mercaptopurineDrug: thioguanineDrug: etoposideDrug: vincristine sulfateDrug: ifosfamideDrug: leucovorin calciumDrug: prednisoneDrug: vindesine
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- University Hospital, Motol
- Target Recruit Count
- 4000
- Registration Number
- NCT00764907
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czech Republic
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: EtoposideBiological: FilgrastimDrug: Hydrocortisone Sodium SuccinateDrug: IfosfamideOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneDrug: PegaspargaseDrug: PrednisoneRadiation: Radiation TherapyDrug: Vincristine Sulfate
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00720109
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2015-01-14
- Target Recruit Count
- 2039
- Registration Number
- NCT00613457
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: AsparaginaseProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneProcedure: EchocardiographyDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: LestaurtinibDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneProcedure: Multigated Acquisition ScanDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneDrug: Therapeutic HydrocortisoneDrug: Vincristine Sulfate
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 218
- Registration Number
- NCT00557193
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 445
- Registration Number
- NCT00550992
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czechia
🇫🇷CHR Hotel Dieu, Nantes, France
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 59
- Registration Number
- NCT00537030
- Locations
- 🇺🇸
Harbor-University of California at Los Angeles Medical Center, Torrance, California, United States
🇺🇸Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.